Clinical application of dendritic cells and interleukin-2 and tools to study activated T cells in horses–first results and implications for quality control.

The research article investigates how an immune response can be fostered in horses through the application of dendritic cells and interleukin-2. It explores how to create an effective protocol involving these agents, monitoring T cell responses, and identifying potential quality control concerns in clinical studies.

Understanding Dendritic Cells and Interleukin-2

• Dendritic Cells (DCs) are a type of white blood cells that present antigens to other immune cells, creating a response. Using these cells in ex vivo studies can support the development of vaccination protocols, particularly for tumour immunology.
• Interleukin-2 (IL-2) is a type of cytokine signaling molecule in the immune system. It regulates white blood cell activity, crucial for a body’s fight against disease.

Study Objectives

• The research had multiple objectives. Firstly, it aimed to test whether autologous DC or recombinant human IL-2 loaded with tumor lysates were well tolerated in horses. Specifically, these treatments were applied to equine sarcoids and squamous cell carcinomas during an exploratory phase I study.
• The research also aimed to create a robust protocol for the magnetic separation of monocytes, a technique often used in human clinical studies.
• Finally, the researchers wanted to highlight the limitations in reagents used to study T cell based immune reactions in horses, particularly those related to CD25 and FoxP3 markers.

Findings and Implications

• The study found that local application of DC or IL-2 resulted in no side effects, indicating its potential tolerance in horses.
• The research also detected that a polyclonal approach to identify antigens, like CD25, could succeed when monoclonal antibodies (mAbs) are not available.
• Experiments showed that mAb FJK16s, used previously in rodents, humans, and dogs, can also be used in horses, broadening its potential use in clinical practices.
• The study authors noted that quality control is crucial in these clinical trials. They suggested adopting multicenter studies, as done in human medicine, to adhere to established standards and benefit veterinary medicine.